Klotho Neurosciences, Inc. Market Cap ($50.59 Million)
Market Cap & Net Worth: Klotho Neurosciences, Inc. (KLTO)
Klotho Neurosciences, Inc. market cap. Klotho Neurosciences, Inc. (NASDAQ:KLTO) has a market capitalization of $50.59 Million ($50.59 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21659 globally and #4852 in its home market, demonstrating a 13.43% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Klotho Neurosciences, Inc.'s stock price $0.47 by its total outstanding shares 108088661 (108.09 Million). Also see Klotho Neurosciences, Inc. (KLTO) cash flow conversion for how efficiently the company converts equity into cash flow.
Klotho Neurosciences, Inc. Market Cap History (2022–2026)
Klotho Neurosciences, Inc. market cap history from 2022 to 2026. Data shows change from $1.09 Billion to $50.59 Million (-54.53% CAGR). Check Klotho Neurosciences, Inc. stock price for real-time trading data and today's change.
Index Memberships
Klotho Neurosciences, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #615 of 976 |
Weight: Klotho Neurosciences, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Klotho Neurosciences, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Klotho Neurosciences, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Klotho Neurosciences, Inc. annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KLTO by Market Capitalization
Companies near Klotho Neurosciences, Inc. in the global market cap rankings as of November 4, 2026. Also see KLTO total assets for a full breakdown of the balance sheet.
Key companies related to Klotho Neurosciences, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Klotho Neurosciences, Inc. (2022–2026)
Market capitalization of Klotho Neurosciences, Inc. from 2022 to today. Between 2022 and today, Klotho Neurosciences, Inc.'s market cap moved from $1.09 Billion to $ 50.59 Million, with a yearly change of -54.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $50.59 Million | +61.94% |
| 2025 | $31.24 Million | -40.41% |
| 2024 | $52.42 Million | -95.47% |
| 2023 | $1.16 Billion | +6.31% |
| 2022 | $1.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Klotho Neurosciences, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $50.59 Million USD |
| MoneyControl | $50.59 Million USD |
| MarketWatch | $50.59 Million USD |
| marketcap.company | $50.59 Million USD |
| Reuters | $50.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed it… Read more